Risa Y. Shibata

Osaka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Effects of Ensitrelvir on the Pharmacokinetics of Combined Oral Contraceptives (Ethinyl Estradiol/Drospirenone) in Healthy Adult Women: A Phase 1 Fixed-Sequence, Multiple-Dose, Drug-Drug Interaction Study.

Effects of Ensitrelvir on the Pharmacokinetics of Combined Oral Contraceptives (Ethinyl Estradiol/Drospirenone) in Healthy Adult Women: A Phase 1 Fixed-Sequence, Multiple-Dose, Drug-Drug Interaction Study.

Journal: Clinical drug investigation

Published: November 14, 2025

Longitudinal antibody titers measured after COVID-19 mRNA vaccination can identify individuals at risk for subsequent infection.

Longitudinal antibody titers measured after COVID-19 mRNA vaccination can identify individuals at risk for subsequent infection.

Journal: Science translational medicine

Published: September 17, 2025

Longitudinal analysis of immune responses to SARS-CoV-2 recombinant vaccine S-268019-b in phase 1/2 prime-boost study.

Longitudinal analysis of immune responses to SARS-CoV-2 recombinant vaccine S-268019-b in phase 1/2 prime-boost study.

Journal: Frontiers in immunology

Published: December 23, 2024

A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults.

A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults.

Journal: Scientific reports

Published: August 01, 2023

Safety and immunogenicity of a booster dose of S-268019-b: Interim findings of a Phase 3, open-label clinical study in Japan.

Safety and immunogenicity of a booster dose of S-268019-b: Interim findings of a Phase 3, open-label clinical study in Japan.

Journal: Vaccine: X

Published: May 24, 2023

Population pharmacokinetics of duloxetine in Japanese pediatric patients with major depressive disorder.

Population pharmacokinetics of duloxetine in Japanese pediatric patients with major depressive disorder.

Journal: Drug metabolism and pharmacokinetics

Published: June 28, 2022

Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study.

Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study.

Journal: Vaccine

Published: April 01, 2022

Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings.

Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings.

Journal: Vaccine

Published: January 14, 2022

Showing 1-8 of 8

Last Updated: 09/26/2026